Previous Chapter Chapter 24: Intravenous Abuse of Methylphenidate Next Chapter

Bjarni O. Rafnar & Gudrun Dora Bjarnadottir

In: The SAGE Handbook of Drug & Alcohol Studies Volume 2

Chapter 24: Intravenous Abuse of Methylphenidate

  • Citations
  • Add to My List
  • Text Size

Intravenous Abuse of Methylphenidate
Intravenous Abuse of Methylphenidate
Bjarni O. RafnarGudrun Dora Bjarnadottir
Introduction

Pharmaceutical stimulants such as methylphenidate (MPH) are considered first-line treatment for symptoms of attention deficit/hyperactivity disorder (ADHD). With growing awareness and understanding of ADHD among the public and the medical community, there has been a steady rise in the production and use of these medications worldwide in the last two decades. Much of the increase has been in the form of MPH in different formulations. The bulk of MPH use has been in the USA but other high prescribing countries include Canada, Norway, Netherlands, Israel and Iceland (INCB, 2012, Scheffler et al., 2007).

Since MPH shares pharmacological effects with substances of abuse, such as amphetamine and cocaine, concerns have been raised about its abuse ...

Looks like you do not have access to this content.

Login

Don’t know how to login?

Click here for free trial login.

Back to Top

Copy and paste the following HTML into your website